SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2013 fourth quarter and full year 2013.
Revenue and Earnings Summary
Revenue for the fiscal 2013 fourth quarter totaled $14.3 million, a 3% increase from $13.8 million reported in the fiscal 2012 fourth quarter. Diluted earnings per share from continuing operations totaled $0.26 compared with $0.17 in the prior-year period.
Help employers find you! Check out all the jobs and post your resume.
